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Cancer therapy and prevention drugs traditionally have devel-
oped along very separate tracks and with very different
approaches, largely because of methods established prior to
certain advances in molecular biology, such as those allowing
analyses of specific growth factor signaling pathways. Early-
phase clinical trials of novel therapy drugs generally establish
the maximum tolerated dose (MTD) in advanced cancer patients
with no options for further standard treatment (Eisenhauer et al.,
2000).This approach emerged as an appropriate strategy for the
development of cytotoxic agents with a narrow window between
their toxic and effective doses, or a narrow therapeutic index.
With toxic effective doses and usually intravenous administra-
tion, these agents were usually inappropriate for prevention.
Early-phase preventive drug development typically has proceed-
ed along far less structured lines that seemed appropriate for
testing relatively nontoxic, frequently widely available agents,
which often were suggested for a role in cancer prevention by
observational and limited preclinical data.
Explosive advances in the molecular understanding of
malignant and premalignant carcinogenesis, cancer risk and
prognosis, and drug effects on relevant molecular targets and
pathways have produced a new generation of molecular-target-
ed drugs with acceptable therapeutic indexes for both prevention
and therapy. Early-phase drug development approaches for pre-
vention and therapy no longer need to be mutually exclusive and
indeed already have begun to converge.This article will focus on
the molecular considerations and underpinnings, clinical set-
tings, and rapid implementation of a practical program of conver-
gent development of cancer prevention and therapy agents.
Molecular considerations of the prevention-therapy
convergence
Many factors facilitate the prevention-therapy convergence,
including a molecular rationale based on our rapidly advancing
understanding of multistep neoplasia, growing recognition of
intraepithelial neoplasia (IEN) and overlapping molecular alter-
ations in IEN and cancer, advancing identification of molecular
high risk associated with IEN, increasing emphasis on oral,
bioavailable small molecules with a wide therapeutic index and
targeting the abnormal molecular biology of neoplasia, and
practical considerations of drug development timelines and the
challenges inherent in identifying qualified novel agents for
clinical trials.
Molecular rationale
Two important concepts support merging the early clinical
development of cancer therapy and prevention agents: (1) “neo-
plasia” includes states of both “precancer” and “cancer,” as elu-
cidated by the multistep molecular signature of human
carcinogenesis (Bishop and Weinberg, 1996); and (2) the
molecular hallmarks of cancer development—evading apopto-
sis, self-sufficiency in growth signals, insensitivity to antigrowth
signals, strong replicative potential, and sustained angiogene-
sis—are frequently present in both cancer and precancer
(Hanahan and Weinberg, 2000). Recent studies suggest that
many of the molecular and biochemical events leading to the
increased proliferation and reduced apoptosis found in precan-
cer and early invasive cancer are the same events that give
cancer cells the ability to invade and metastasize (Bernards and
Weinberg, 2002; Hynes, 2003).Therefore, the molecular targets
relevant to advanced cancer likely also are relevant to precan-
cer, supporting the argument that early assessments of novel
drugs can be relevant to both prevention and therapy.
IEN
Illustrated by exquisite models of multistep oral and colorectal
carcinogenesis (Califano et al., 1996; Vogelstein et al., 1988),
IEN is a noninvasive lesion representing an often pathologically
discernable intermediate state between normal epithelium and
invasive cancer. Clinically relevant IEN has genetic abnormali-
ties, loss of cellular control, phenotypic characteristics overlap-
ping those of invasive cancer, and a substantial risk of cancer or
biologically aggressive, potentially lethal cancer. The cancer
risk of an IEN is a key issue in its selection as a relevant preven-
tion endpoint for convergent drug development; molecular risk
models, including those with somatic and constitutional genetic
alterations (Spitz et al., 2004), will play an important role in
assessing this risk (as well as cancer prognosis). Highest-risk
IEN, e.g., in the colorectal region and oral cavity, will be espe-
cially useful for convergent drug development, as detailed later.
The colorectal IEN familial adenomatous polyposis (FAP) is
associated with a virtually 100% risk of colorectal cancer
(Steinbach et al., 2000). High-risk oral IEN includes that with
aneuploidy, which is associated with over a 50% risk of biologi-
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cally aggressive oral cancer (Sudbo et al., 2004), or that with
allelic imbalance (Lippman and Hong, 2001). IENs have varying
degrees of cancer risk (depending on the organ site and specif-
ic lesion) (O’Shaughnessy et al., 2002), and some IENs are
potentially less informative (e.g., because of a low transforma-
tion rate) than others as endpoints for drug development.
The diagnosis of IEN is increasing, probably largely
because of the general aging of the population and because of
technological advances, such as improvements in noninvasive
imaging, endoscopic techniques, and molecular diagnostics.
Even in the pancreas and other sites of aggressive malignan-
cies with poor accessibility and incompletely characterized
early-stage neoplasia, IENs and other early neoplastic lesions
are beginning to be identified, have many genetic and molecular
alterations also found in advanced cancer, and so are potential
targets for prevention and therapy (Corless et al., 2002; Hruban
et al., 2000; Li et al., 2004).
Molecular-targeted study in therapy and prevention
The primarily cytotoxic therapy agents developed in the past
often affected fairly nonspecific targets such as DNA or tubulin.
The dose, toxicity, and therapeutic effect of these agents gener-
ally are directly related, i.e., toxicity correlates with and so
serves as a surrogate for activity. The phase II dose expected to
provide a reasonable therapeutic index in cancer (and frequent-
ly too toxic for prevention) was derived from the phase I-defined
MTD and pharmacokinetics. The MTD remains the primary out-
come of many phase I trials, although new drugs increasingly
modulate specific molecular targets (e.g., specific enzymes)
involved in cell signaling, angiogenesis, or metastasis
(Parulekar and Eisenhauer, 2004). The MTD likely continues to
be used in phase I therapy trials because of the complexity and
logistics of using molecular/cellular endpoints, unclear mecha-
nisms of many drugs, and the argument that the MTD may have
the greatest potential efficacy in cancer patients (Korn, 2004).
The MTD, however, may not be the optimal outcome of
phase I testing of agents with more cytostatic activity profiles, or
with a dose, toxicity, and response that frequently are not direct-
ly related.These agents may substantially modulate a molecular
target, possibly even reaching a plateau in this activity, at doses
well below that of dose-limiting toxicity, reducing the utility of tox-
icity as an activity surrogate. Therefore, it is extremely important
for phase I dose escalation trials of molecular-targeted agents to
attempt to define a range of doses that affect the agent’s molec-
ular target. These agents may also demonstrate dose respon-
siveness ranging well into the toxic end of the spectrum. An
active dose well below dose-limiting toxicity or the MTD is impor-
tant for the chronic dosing typical of prevention, and higher, more
toxic doses may be suitable for cancer therapy.
Emerging data on cyclooxygenase-2 (COX-2) and its
inhibitors in the colon provide a clear example of overlapping
molecular targets for prevention and therapy. Early work show-
ing that COX-2 was not expressed in normal colon cells and
was expressed progressively in colon polyps (adenomas) and
cancer led to testing nonsteroidal antiinflammatory drugs
(NSAIDs) that specifically target (and inhibit) COX-2 (and thus
downstream prostaglandin E2 [PGE2]) for colorectal cancer pre-
vention. (These NSAIDs were developed initially for arthritis.)
COX-2 also appears to be a key mediator of numerous cancer-
related processes, including angiogenesis and mechanisms
leading to invasion and metastasis (Dannenberg and
Subbaramaiah, 2003; Thun et al., 2002). The selective COX-2-
inhibitor celecoxib significantly reduced polyp burden and led to
the U.S. Food and Drug Administration (FDA) approval of cele-
coxib as an adjunct to surgery in FAP patients (Steinbach et al.,
2000). The active dose of this agent (400 mg/bid) has been
shown to inhibit its target in pharmacodynamic studies within
both cancer (Altorki et al., 2003) and IEN (L.J.Wirth et al., 2003,
Proc. Frontiers in Cancer Prev. Res., abstract), and celecoxib
induced apoptosis and inhibited proliferation in the adenomas
of responsive FAP patients (Sinicrope et al., 2004). The NSAID
sulindac also significantly reduced the polyp burden of FAP
patients (Giardiello et al., 1993) and did so in correlation with
the inhibition of protaglandins (PGE2 and F2) (Nugent et al.,
1996) and proliferation (Nugent et al., 1993). Recent research
has identified other pathways related to COX-2—e.g., pathways
involving 15-lipoxygenase-1 (Hsi et al., 2004; Shureiqi et al.,
2002), β-catenin (Boon et al., 2004), peroxisome proliferator-
activated receptor (PPAR)-delta (He et al., 1999; Shureiqi et al.,
2003), and transactivation of epidermal growth factor receptor
(EGFR) signaling (Dannenberg et al., 2004; Pai et al., 2002)—
that will improve our understanding of and provide new preven-
tive and therapeutic targets for treating colorectal neoplasia.
The oral cavity and breast also have overlapping molecular
targets suitable for prevention and therapy. Aneuploid oral IEN
shares several molecular targets, including EGFR and COX-2,
with oral cancer. The coexistence of these targets and interac-
tions of their signaling pathways (Torrance et al., 2000) support
combinatorial approaches in aneuploid oral IEN. Phase I thera-
py testing of EGFR inhibitors has produced candidate agents
for oral cancer therapy (Cohen et al., 2003) and for prevention in
aneuploid IEN patients. Similarly, the inactivation/mutation of
p53 is an important event in advanced oral IEN and cancer, and
targeting p53 has produced promising results in oral cancer
prevention (Rudin et al., 2003) and therapy (Clayman et al.,
1998; Khuri et al., 2000). Regarding the breast, HER2 is associ-
ated with high-grade ductal carcinoma in situ (Hoque et al.,
2002) and a poor prognosis in breast cancer patients (Slamon
et al., 1987), supporting the development of new oral HER2-tar-
geted drugs (Rusnak et al., 2001) for breast cancer prevention
and therapy. With highly specific rather than pleiotropic molecu-
lar effects, targeted agents may be more effective in earlier neo-
plasia (with fewer genetic alterations) than in advanced cancer
(with more genetic alterations and tumor heterogeneity).
Molecular-targeted drug development issues
Practical drug development issues also support a convergent
drug development approach. Laboratory research is producing
an avalanche of molecular targeted agents with improving ther-
apeutic indexes that emphasize the importance of streamlining
the drug development process. Traditional drug development
requires extremely long timelines for drug discovery, target vali-
dation, clinical development, and regulatory approval.
Therefore, it is imperative that we develop innovative strategies
that integrate early-phase prevention and therapy studies. A
convergent approach will accelerate the drug development
process, from introducing a novel molecular-targeted agent to
producing the final results of a measurable clinical benefit for
FDA review.
A practical model for the prevention-therapy convergence
This section outlines a practical program for implementing the
convergence of cancer therapy and prevention drug develop-
ment. Overlapping prevention-therapy targets and endpoints
would be identified from molecular models of the cancer risk
associated with IEN and of the development and progression of
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cancer and IEN. This new approach integrates prevention end-
points into early-phase dose-escalation trials, which could be
conducted in a mixed cancer population (traditional) or
advanced specific-cancer population (when an agent shows
compelling preclinical activity in a specific cancer). Whenever
feasible, an imbedded prevention endpoint that examines the
impact of the agent on a specific IEN should be integrated with-
in phase I trials in specific cancer patients. Pharmacodynamic
molecular effects involving targets and signaling pathways in
broad phase I trials enrolling all cancer types would be
assessed in an easily accessed surrogate tissue, such as the
skin or peripheral blood mononuclear cells. For example, early
clinical testing of EGFR inhibitors assessed phosho-EGFR in
the normal skin of advanced cancer patients (Albanell et al.,
2002), and early clinical testing of mammalian target of
rapamycin (mTOR) inhibitors assessed inactivation of ribosome
protein S6 kinase in peripheral blood mononuclear cells (Boulay
et al., 2004). Molecular endpoints in a phase I trial conducted in
specific-cancer patients would be measured in tumor tissue or
the relevant IEN to get a clear picture of target-tissue effects.
Clinical effects on the IEN and cellular effects (proliferation,
apoptosis, angiogenesis) also would be monitored and evaluat-
ed for associations or correlations with the agent’s molecular
effects in deciding whether a particular agent should proceed in
development for cancer prevention. Phase I pharmacokinetic
assessments of the drug levels can determine the phase II
dose, as occurred with HER2-targeting trastuzumab (Leyland-
Jones et al., 2003). The overall potential of phase I testing is to
determine a range of biologically active doses (potentially
including the MTD) for further therapy and prevention testing.
Convergent phase II trials are more conducive (than are
phase I trials) to imbedding IEN endpoints within trials conduct-
ed in advanced specific-cancer populations. The clinical effect
of an agent on an imbedded IEN would be an important inde-
pendent factor in deciding on future development for prevention.
Convergent phase II trials also could be conducted (in the same
time frame) in advanced cancer patients without an imbedded
IEN and in IEN populations (most likely high-risk) without can-
cer. High-risk IEN would be preferable to all- or low-risk IEN, as
it would provide better evidence of a potential preventive benefit
and allow a better risk-benefit relationship for testing an investi-
gational new agent. Molecular, cellular, and clinical evidence
from the cancer-only setting could be compelling for prevention,
just as such evidence from studies of IEN-only patients could be
compelling for therapy. These complementary benefits are illus-
trated by celecoxib (400 mg/bid), which was suggested by pre-
vention-related results in the high-risk IEN FAP for testing in
colorectal cancer therapy (Koehne and Dubois, 2004).
Another important phase II model is short-term multiple-
dose trials in preresection, earlier-stage cancer patients, whose
resection tissue specimens lend themselves to assessments of
target-site pharmacokinetics and pharmacodynamics in (and
which may differ by) cancer, IEN, and normal-appearing tissue.
For example, phase II preresection testing of a farnesyl trans-
ferase inhibitor in head and neck cancer patients (M.S. Kies et
al., 2001, Proc. Amer. Assoc. Cancer Res., abstract) has pro-
duced promising results applicable to both prevention and ther-
apy.This model can assess the effects of a range of doses (e.g.,
doses selected specifically for their potential benefit in IEN or
early or advanced cancer patients). Preresection patients typi-
cally have untreated cancers that are less drug-resistant and so
are more amenable to activity assessments than are advanced,
heavily pretreated cancers. This model also can help select or
exclude potential patients for longer-term phase II testing, as
demonstrated by the ability of presurgical testing to identify
tamoxifen’s clear selectivity for estrogen-receptor (ER)-positive
(versus ER-negative) breast tumors (Assersohn et al., 2003).
Limited inherently by a short duration and the requirement to
not compromise subsequent standard surgery and care, the
preresection model may be too short-term to detect drug activi-
ty or unexpected toxicity.Therefore, preresection models should
be used only as adjuncts to other, longer-term phase II trials.
Phase III trials of agents with promise (acceptable toxicity,
target/pathway modulation, cellular and clinical effects on IEN
and/or cancer) demonstrated in early-phase trials would be
conducted separately for therapy and prevention. Whenever
feasible, phase III prevention trials should assess whether can-
cer development correlates with the relevant IEN outcome,
thereby helping to inform future early-phase testing and
addressing the IEN’s validity as a surrogate phase III endpoint.
Phase III, as well as phase II, trials also should assess the
molecular profiles of neoplasia to determine which IENs or can-
cers most likely will respond to a targeted agent (Spitz et al.,
2004). For example, cyclin-D1 polymorphisms can mark the
sensitivity of patients with advanced head and neck IEN to
isotretinoin (likely related to effects on ubiquitin-dependent pro-
teolysis) (Izzo et al., 2003), somatic activating EGFR mutations
can predict response to gefitinib in non-small-cell lung cancer
patients (Lynch et al., 2004; Paez et al., 2004), and mutations 
in KIT or platelet-derived growth factor receptor α predict
response to imatinib in patients with gastrointestinal stromal
tumors (Heinrich et al., 2003a, 2003b). Proteomic and genomic
profiles may also indicate sensitivity to targeted agents, e.g., the
sensitivity of patients with the advanced colorectal IEN FAP to
celecoxib (proteomic) (Xiao et al., 2004) and of patients with
ER-positive breast cancer to tamoxifen (genomic) (S. Paik et al.,
2003, Breast Cancer Res., abstract).
Colorectal neoplasia is an excellent setting for imbedding
an IEN endpoint in a phase I or II clinical trial conducted in an
advanced cancer population. The impact of novel agents on the
early clonal precursor of colorectal cancer, dysplastic aberrant
crypt foci (ACF), could be examined in a phase I or II trial in
advanced colorectal cancer patients, who typically have a high
rate of ACF. Dysplastic ACF share many of the molecular alter-
ations associated with adenomas and invasive colon cancer
(Cheng and Lai, 2003). ACF in rectal mucosa can be accurately
quantified and are responsive to clinically active interventions
such as sulindac (Giardiello et al., 1993; Takayama et al., 1998)
and aspirin (Baron et al., 2003; Shpitz et al., 2003). Therefore,
advanced colon cancer patients on early clinical trials of novel
agents with potential for colon cancer prevention could be seri-
ally examined using flexible sigmoidoscopy for the impact of the
novel agent on rectal ACF. Effects on rectal dysplastic ACF
(molecular, cellular, and clinical) could provide important
insights into an agent’s dose and toxicity, setting the stage for
more definitive testing in patients with more advanced states of
colorectal IEN, such as large and/or villous colorectal adeno-
mas. Early-phase cancer trials with imbedded IENs would
greatly accelerate prevention-therapy drug development. This
approach will become increasingly feasible as new molecular
and functional imaging techniques come on line for monitoring
serial target-tissue changes (Morgan et al., 2003; Rao et al.,
2003).
Oral neoplasia is another excellent setting for phase II study
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in high-risk IEN patients without cancer. As outlined above, it is
possible to identify oral IEN patients (primarily those with DNA
aneuploidy) at a high risk for progression to invasive cancer and
death, and this IEN has molecular targets, e.g., COX-2 overex-
pression and EGFR activation, that overlap with targets in oral
cancer patients (Dannenberg et al., 2004). With no standard
effective preventive treatment (Sudbo et al., 2004), aneuploid
oral IEN patients are an appropriate population for the phase II
study of novel drugs.
The practical implementation of convergent drug develop-
ment also faces important hurdles and challenges. It has been
difficult to identify IEN patients at the greatest risk of invasive
cancer for phase II trials. Clinical trials of molecular-targeted
agents are complex (e.g., because of issues involving serial
biopsies and target and assay validations) (Korn, 2004;
Parulekar and Eisenhauer, 2004; Tubbs et al., 2001). It can be
difficult to define the range of biologically active doses of target-
ed agents. There are also national regulatory obstacles to con-
vergent development. For example, calling the clinical setting
“prevention” or “therapy” can lead regulatory agencies to make
different decisions on the same agent in similar patient popula-
tions. Recognizing the potential for this problem, the FDA has
created the new Office of Oncology Drug Products to eliminate
cross-FDA Division inconsistencies in evaluating cancer pre-
vention and therapy drugs.
Conclusions
Cancer prevention and therapy are converging and will continue
to converge at the level of novel drug development. With the
explosion of promising new molecular targeted drugs, the
mounting costs of drug development, and the continuing high
incidences and mortality rates of major cancers, it is urgent that
prevention and therapy researchers collaborate to efficiently
credential new drugs capable of treating the full range of neo-
plasia, from IEN to metastatic disease. An efficient and conver-
gent drug development program could relatively quickly sort out
the most from the least promising candidates among the many
new molecular-targeted agents, accelerate promising new
agent development for use in cancer prevention, and put
unpromising agents on hold at a relatively early stage in the
drug development process.
Although none have been developed convergently, molecu-
lar targeted drugs are already in late-stage clinical study or are
FDA approved for both prevention and therapy. The selective
estrogen-receptor modulator (SERM) tamoxifen moved from full
clinical development and FDA approval for breast cancer thera-
py into clinical development and FDA approval for several breast
cancer prevention settings (Lippman and Brown, 1999). The
COX-2 inhibitor celecoxib has moved from FDA approval in a
cancer prevention setting into cancer therapy trials (e.g., com-
bined with other agents) (Dannenberg and Subbaramaiah,
2003; Koehne and Dubois, 2004), whereas aromatase inhibitors
have moved from FDA-approved cancer therapy into cancer
prevention trials (Dunn et al., 2004). It is not always even clear
whether targeted drugs are preventing or treating subclinical
cancer, as has been argued with respect to tamoxifen in the
Breast Cancer Prevention Trial (Lippman and Brown, 1999) and
finasteride in the Prostate Cancer Prevention Trial (Thompson
et al., 2003), or whether the clinical setting represents precan-
cer (prevention) or subclinical cancer (therapy) (Lippman and
Hong, 2002), as illustrated by the conjoined prevention (of sec-
ond primary tumors) and adjuvant therapy/recurrence settings
involving curatively resected cancer patients (Leong et al.,
1998; Swain et al., 2004).
The current inefficient system of serially developing drugs
for therapy then prevention and vice versa creates unnecessary
expense and delay in improving the public health via the full
range of benefits offered by molecular-targeted drugs such as
SERMs. Innovative convergent drug development may eventu-
ally redefine cancer, emphasizing molecular over physical/
invasion characteristics. In a future of fully converged drug
development, an invasive lesion with a low molecular risk of
recurrence or mortality may be managed less aggressively than
would be a preinvasive lesion with a very high molecular risk of
advanced cancer and mortality. Intervening effectively in the full
range of neoplasia promises to accelerate the progress of
oncology toward achieving its major goal of eliminating the dire
consequences of the major cancers.
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